Limits...
Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases.

Takagi T, Katagiri H, Kim Y, Suehara Y, Kubota D, Akaike K, Ishii M, Mukaihara K, Okubo T, Murata H, Takahashi M, Kaneko K, Saito T - PLoS ONE (2015)

Bottom Line: Lung cancer was identified in 72 (25.2%) cases, and was the most frequently observed primary lesion.The median survival times of prostate cancer cases was over 120 months, that of patients with primary lung cancers was 9.0 months and the median survival time of cases who were finally diagnosed with an unknown primary was 11.0 months.We believe that our study would contribute to establishing an optimal strategy for diagnosing the primary site in SMUP patients, and our data provide definite indications for the survival times for different SMUP situations.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedic Surgery, Juntendo University School of Medicine, Tokyo, Japan; Department of Orthopaedic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.

ABSTRACT

Background: Skeletal metastasis is a common metastatic event for several carcinomas, and the treatment for skeletal metastasis of unknown primary (SMUP) are a critical issue in cancer therapy. Making a diagnosis of the primary site is the most crucial step in the treatment of SMUP; however, the procedures are sometimes difficult and time-consuming, and the primary site often remains unknown. Therefore, to establish optimal diagnostic strategies and elucidate the overall survival rates of SMUP, we conducted this retrospective study.

Methods: We retrospectively analyzed the clinical data for 286 SMUP cases from a total of 2,641 patients with skeletal metastases who were treated between 2002 and 2014 at our initiations.

Results: The primary sites were identified in 254/286 patients (88.8%), while 32 (11.2%) primary sites were not detected by our diagnostic strategies. Lung cancer was identified in 72 (25.2%) cases, and was the most frequently observed primary lesion. The median survival time of the SMUP patients was 20.0 months, while the median survival times of solitary bone metastasis cases and multi-bone metastasis cases were 39.0 months and 16.0 months, respectively. The median survival times of prostate cancer cases was over 120 months, that of patients with primary lung cancers was 9.0 months and the median survival time of cases who were finally diagnosed with an unknown primary was 11.0 months.

Conclusions: We believe that our study would contribute to establishing an optimal strategy for diagnosing the primary site in SMUP patients, and our data provide definite indications for the survival times for different SMUP situations.

No MeSH data available.


Related in: MedlinePlus

The Kaplan-Meier survival curves show the overall survival rates for each primary site of the SMUP cohort.A: lung cancers, B: blood cell tumors (including multiple myelomas and malignant lymphomas), C: Unknown (still unknown origin after the nine steps) and D: prostate cancers.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4482691&req=5

pone.0129428.g001: The Kaplan-Meier survival curves show the overall survival rates for each primary site of the SMUP cohort.A: lung cancers, B: blood cell tumors (including multiple myelomas and malignant lymphomas), C: Unknown (still unknown origin after the nine steps) and D: prostate cancers.

Mentions: The median overall survival was 20.0 months (range, 1 to 131 months) in the 286 SMUP patients. The survival analysis of each primary tumor type revealed that the median survival times were as follows: 9.0 months for lung cancer, 105.0 months for myeloma, 11.0 months for unknown origin, over 120.0 months for prostate cancer, over 82.0 months for lymphoma, 16.0 months for kidney cancer, 7.0 months for liver cancer, 34.0 months for breast cancer, 12.0 months for gastric cancer, 15.0 months for pancreatic cancer, 84.0 months for thyroid cancer, 12.0 months for bile duct cancer, 14.0 months for colon cancer, 11.0 months for esophageal cancer, 43.0 months for thymoma, 23.0 months for submaxillary gland cancer, 31.0 months for vaginal cancer, 12 months for urachal cancer and 120.0 months for testicular cancer (Fig 1A–1D, Table 2).


Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases.

Takagi T, Katagiri H, Kim Y, Suehara Y, Kubota D, Akaike K, Ishii M, Mukaihara K, Okubo T, Murata H, Takahashi M, Kaneko K, Saito T - PLoS ONE (2015)

The Kaplan-Meier survival curves show the overall survival rates for each primary site of the SMUP cohort.A: lung cancers, B: blood cell tumors (including multiple myelomas and malignant lymphomas), C: Unknown (still unknown origin after the nine steps) and D: prostate cancers.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4482691&req=5

pone.0129428.g001: The Kaplan-Meier survival curves show the overall survival rates for each primary site of the SMUP cohort.A: lung cancers, B: blood cell tumors (including multiple myelomas and malignant lymphomas), C: Unknown (still unknown origin after the nine steps) and D: prostate cancers.
Mentions: The median overall survival was 20.0 months (range, 1 to 131 months) in the 286 SMUP patients. The survival analysis of each primary tumor type revealed that the median survival times were as follows: 9.0 months for lung cancer, 105.0 months for myeloma, 11.0 months for unknown origin, over 120.0 months for prostate cancer, over 82.0 months for lymphoma, 16.0 months for kidney cancer, 7.0 months for liver cancer, 34.0 months for breast cancer, 12.0 months for gastric cancer, 15.0 months for pancreatic cancer, 84.0 months for thyroid cancer, 12.0 months for bile duct cancer, 14.0 months for colon cancer, 11.0 months for esophageal cancer, 43.0 months for thymoma, 23.0 months for submaxillary gland cancer, 31.0 months for vaginal cancer, 12 months for urachal cancer and 120.0 months for testicular cancer (Fig 1A–1D, Table 2).

Bottom Line: Lung cancer was identified in 72 (25.2%) cases, and was the most frequently observed primary lesion.The median survival times of prostate cancer cases was over 120 months, that of patients with primary lung cancers was 9.0 months and the median survival time of cases who were finally diagnosed with an unknown primary was 11.0 months.We believe that our study would contribute to establishing an optimal strategy for diagnosing the primary site in SMUP patients, and our data provide definite indications for the survival times for different SMUP situations.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedic Surgery, Juntendo University School of Medicine, Tokyo, Japan; Department of Orthopaedic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.

ABSTRACT

Background: Skeletal metastasis is a common metastatic event for several carcinomas, and the treatment for skeletal metastasis of unknown primary (SMUP) are a critical issue in cancer therapy. Making a diagnosis of the primary site is the most crucial step in the treatment of SMUP; however, the procedures are sometimes difficult and time-consuming, and the primary site often remains unknown. Therefore, to establish optimal diagnostic strategies and elucidate the overall survival rates of SMUP, we conducted this retrospective study.

Methods: We retrospectively analyzed the clinical data for 286 SMUP cases from a total of 2,641 patients with skeletal metastases who were treated between 2002 and 2014 at our initiations.

Results: The primary sites were identified in 254/286 patients (88.8%), while 32 (11.2%) primary sites were not detected by our diagnostic strategies. Lung cancer was identified in 72 (25.2%) cases, and was the most frequently observed primary lesion. The median survival time of the SMUP patients was 20.0 months, while the median survival times of solitary bone metastasis cases and multi-bone metastasis cases were 39.0 months and 16.0 months, respectively. The median survival times of prostate cancer cases was over 120 months, that of patients with primary lung cancers was 9.0 months and the median survival time of cases who were finally diagnosed with an unknown primary was 11.0 months.

Conclusions: We believe that our study would contribute to establishing an optimal strategy for diagnosing the primary site in SMUP patients, and our data provide definite indications for the survival times for different SMUP situations.

No MeSH data available.


Related in: MedlinePlus